Skip to main content

Table 2 Statistical correlation of anti-NMDAR antibody with developmental milestones in the patient group of the study

From: N-Methyl-d-aspartate (NMDA) receptor antibody in relation to autism spectrum disorder (ASD): presence and association with symptom profile

Parameter NMDA Test of significance
Negative Positive
Mean ± SD Mean ± SD Value p-value Sig.
N (%) N (%)
Gross motor milestones Adequate 44 (68.75%) 23 (100%) X2 = 9.33 0.002(C) S
Delayed 20 (31.25%) 0 (0%)
Fine motor milestones Adequate 33 (51.56%) 20 (86.96%) X2 = 8.90 0.003(C) S
Delayed 31 (48.44%) 3 (13.04%)
Speech stage Preverbal 55 (85.94%) 14 (60.87%)   0.017(F) S
Phrase 9 (14.06%) 9 (39.13%)
Regression None reported 28 (43.75%) 7 (30.43%) X2 = 1.248 0.264(C) NS
Present 36 (56.25%) 16 (69.57%)
Age when regression was noticed—months 9 (0–24) 12 (0–24) U = 677.0 0.554(M) NS
  1. SD Standard deviation, N Number, S Significant, NS Not significant, (T)Student’s t-test of significance (t = Student’s t-test value). (C)Chi-square test of significance (X2 = chi-square test value). (F)Monte-Carlo Fisher’s exact test of significance. (M)Mann-Whitney’s test of significance (U = Mann-Whitney’s test value)